For the quarter ended June 2026, Perrigo (PRGO Quick QuotePRGO - Free Report) reported revenue of $1.02 billion, down 3.2% over the same period last year. EPS came in at $0.50, compared to $0.57 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $1 billion, representing a surprise of +1.89%. The company delivered an EPS surprise of +61.29%, with the consensus EPS estimate being $0.31.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Perrigo performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net Sales- Self Care: $577 million versus $581.24 million estimated by two analysts on average.
• Net Sales- Specialty Sciences: $227 million compared to the $236.54 million average estimate based on two analysts.
• Net Sales- All Other: $119 million compared to the $102.73 million average estimate based on two analysts.
• Net Sales- Infant Formula: $101 million compared to the $85.32 million average estimate based on two analysts.

View all Key Company Metrics for Perrigo here>>>

Shares of Perrigo have returned -3.7% over the past month versus the Zacks S&P 500 composite's +3.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.